A Phase 2 interventional study of JNJ-64042056 and Placebo in Alzheimer Disease, sponsored by Janssen Pharmaceutica N.V., Belgium. Active, not recruiting at 90 sites in 9 countries. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Alzheimer Disease by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · Johnson & Johnson.
Among the 61 studies in Alzheimer Disease by Johnson & Johnson, this one is the 36th largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 2, and was the 61st registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 61 studies in Alzheimer Disease by Johnson & Johnson is open now, in 10 countries. Recruiting first, the newest first:
Intra-Cellular Therapies, Inc. · Sites in United States, Bulgaria, Croatia and 7 more countries
Ages 55+
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 8 · Phase 3 25 · Phase 4 5
First in 1995; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 108 across the 50 interventional studies, 1,109 across the 10 observational. Of the 59 that completed or were terminated, 9 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Pharmaceutica N.V., Belgium, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutica N.V., Belgium is the lead sponsor of 58 studies on the registry; none are open to participants now.
1 of the studies in Alzheimer Disease by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06544616Janssen Pharmaceutica N.V., BelgiumA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | 2026-12-22 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies in Alzheimer Disease by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intramuscular (IM) injection of JNJ-64042056 from Week 0 up to a maximum of Week 76.
Drug: JNJ-64042056
Participants will receive IM injection of placebo from Week 0 up to a maximum of Week 76.
Drug: Placebo
JNJ-64042056 will be administered intramuscularly.
Placebo will be administered intramuscularly.
Change From Baseline in Brain Tau Burden as Measured by Tau PET in Specified Regions of Interest (ROI)
Change from baseline in brain tau burden, as measured by tau PET (including but not limited to Braak I-VI ROIs, tau naive composite ROI, Connection Rank ROI, and New Tau Composite ROI Volume) will be reported.
Time frame: Baseline up to Week 102
Levels of IgG Titers Against Enriched Paired Helical Filaments (ePHF), p-tau and tau in Serum
Levels of IgG titers against ePHF, p-tau peptide and tau peptide in serum will be measured.
Time frame: Up to Week 102
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical or biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Time frame: Up to Week 104
Number of Participants With Reactogenicity
Solicited AEs will be used to assess the reactogenicity of the active immunotherapy and are predefined local (at the injection site) and systemic events for which the participant is specifically questioned, and which are noted by participants in their participant diary.
Time frame: Up to Week 78
Number of Participants with Vital Signs Abnormalities
Participants with vital signs abnormalities including temperature and blood pressure (systolic and diastolic) (supine) will be summarized over time.
Time frame: Up to Week 102
Number of Participants with Clinical Laboratory Abnormalities
Participants with clinical laboratory abnormalities values (chemistry, hematology, urinalysis and coagulation) will be reported.
Time frame: Up to Week 102
Change from Baseline in Electrocardiogram (ECG) Values
Change from baseline in ECG values will be reported.
Time frame: Baseline up to Week 102
Change From Baseline in Columbia-Suicidality Severity Rating Scale (C-SSRS)
A frequency distribution of C-SSRS scores at each scheduled time point by treatment will be provided. Shifts from the baseline visit to the most severe/maximum score during the treatment period will be summarized by treatment. The maximum score assigned for each participant will also be summarized into 1 of 3 categories: no suicidal ideation or behavior (0), suicidal ideation (1 to 5), suicidal behavior (6 to 10).
Time frame: Baseline up to Week 102
Change From Baseline in Magnetic Resonance Imaging (MRI) Findings
Change from baseline in brain MRI safety findings will be reported.
Time frame: Baseline up to Week 102
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · www.jnj.com
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 29 months is above that.
Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Pharmaceutica N.V., Belgium →